Mitochondrial Bioenergetics: The Three-Compound Longevity Stack

The longevity research space has accumulated a long list of compounds with weak human evidence and strong marketing claims. Most do not survive a rigorous read of the published literature.

Three that do — at least to the extent that the underlying mechanism is well-characterized and the early human data is meaningful — are NAD+, SS-31 (also called elamipretide), and MOTS-c. All three operate on the mitochondrial side of cellular biology.

This piece walks through what each does, what the human evidence supports, the practical effect users describe most consistently, and how the three compose as a stack.

NAD+: the cofactor that controls cellular energy

Nicotinamide adenine dinucleotide is a coenzyme present in every living cell. It exists in two forms — oxidized (NAD+) and reduced (NADH) — and shuttles electrons through the metabolic machinery. ATP production, glycolysis, the citric acid cycle, oxidative phosphorylation — all of them require NAD+ to function.

NAD+ also serves as a substrate for several non-redox enzymes. Sirtuins, the family of NAD+-dependent enzymes linked to longevity research, consume NAD+ to function. PARPs, the DNA repair enzymes, consume NAD+ during repair. The pool size of NAD+ in a cell is therefore not just a metabolic quantity — it is a signal that influences cellular maintenance, DNA repair, and stress response.

NAD+ levels decline with age. Multiple studies in human tissue have documented this — skin, muscle, liver, brain. By age 60, tissue NAD+ pools are typically half of what they were at 30 in many tissues.

The human evidence on NAD+ supplementation:

**NAD+ precursor supplementation.** Several human trials of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have demonstrated dose-dependent elevation of blood NAD+ levels.

**Direct NAD+ administration.** The literature on subcutaneous and IV NAD+ is smaller but more direct. The bioenergetic effects in research models are robust; human pilot data on cognitive and energy outcomes are encouraging.

**Outcome studies.** A multi-center 2023 trial in adults with mild cognitive impairment showed NMN supplementation improved cognitive performance markers versus placebo.

The most consistently reported user effect — and the one that surprises people new to NAD+ — is mid-day cognitive clarity. The afternoon haze that is a common feature of life past 35 often improves on a multi-week NAD+ protocol.

SS-31: the cardiolipin-targeted tetrapeptide

SS-31 (also known as elamipretide) is a synthetic four-amino-acid peptide that selectively targets cardiolipin, a phospholipid present almost exclusively in the inner mitochondrial membrane. The compound was developed at Cornell.

The mechanism is elegant. Cardiolipin is essential for the function of the electron transport chain — it stabilizes the protein complexes that produce ATP. As mitochondria age and accumulate oxidative damage, cardiolipin becomes peroxidized; the electron transport chain becomes inefficient; ATP production drops while reactive oxygen species production rises.

SS-31 binds cardiolipin and protects it from peroxidation. The result is preserved mitochondrial function under oxidative stress conditions — improved ATP production, reduced reactive oxygen species, restored bioenergetic capacity.

The human evidence:

**Mitochondrial myopathy (Annals of Neurology, 2017).** A randomized trial of elamipretide in adults with primary mitochondrial myopathy showed improvements in walk distance and muscle function on multi-week dosing.

**Heart failure (Circulation, 2018).** A pilot trial in adults with heart failure with reduced ejection fraction showed improvements on elamipretide infusion.

**Age-related muscle dysfunction (Aging Cell, 2018).** A study in older adults demonstrated improvements in mitochondrial function measurable by spectroscopy after elamipretide treatment.

**Geographic atrophy.** Phase 2 ophthalmology trials suggested visual function improvement in geographic atrophy, a condition driven by mitochondrial dysfunction in retinal cells.

MOTS-c: the mitochondrial-derived peptide

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA itself. This is unusual. Most peptide hormones are encoded in the nuclear genome. MOTS-c is encoded in mitochondria, translated in the cytoplasm, and signals between mitochondria and the rest of the cell about metabolic state.

It is a relatively recent discovery — first described in 2015 by Pinchas Cohen's lab at USC. The mechanism work over the past decade has demonstrated:

- MOTS-c improves insulin sensitivity in skeletal muscle - MOTS-c activates AMPK, a master metabolic regulator - MOTS-c levels in human blood decline with age - Higher endogenous MOTS-c levels correlate with metabolic flexibility and exercise capacity

The most distinctive practical effect users report is metabolic flexibility — the body's ability to switch between fuel sources (glucose versus fat) efficiently. People stuck in carbohydrate-dominant metabolism often describe feeling more steady-state energy on multi-week MOTS-c protocols, with less of the post-meal energy crash.

How they compose as a stack

The mechanistic case for using all three is that they target different layers of the same machinery:

- **NAD+** maintains the cofactor pool that powers ATP production and supports DNA repair, sirtuin activity, and PARP function. It is the substrate. - **SS-31** protects the mitochondrial membrane that the electron transport chain operates in. It is the structural protection. - **MOTS-c** signals to the rest of the cell about metabolic state and supports insulin sensitivity. It is the regulatory signal.

Substrate, structure, signal. Different layers, complementary effects.

Practical effects in order of appearance

What users describe, in roughly the order it appears:

**Week 1 to 2: Cognitive clarity.** The mid-day haze that comes from age-related NAD+ decline often resolves first. Mental energy through the afternoon is the earliest detectable subjective change.

**Week 2 to 4: Sustained energy.** Steady-state energy through the day improves. The post-lunch slump softens. Recovery between training sessions feels faster.

**Week 4 to 8: Body composition shifts.** Slow but consistent — lean mass holds, body fat slowly decreases, particularly around the midsection. Not dramatic on the scale but measurable on body composition assessments.

**Month 2+: Metabolic flexibility.** The big-picture effect is improved metabolic flexibility — fewer energy crashes, better tolerance of fasting, more stable mood through the day. This is the underrated effect of the stack and the one that has the most practical day-to-day impact.

Who this stack is for

The longevity research compounds are not weight-loss tools. They are not strength tools alone. They are cellular-bioenergetic tools. The investigators who get the most out of this category are those who:

- Have the basics handled (sleep, training, nutrition) - Are seeking the kind of incremental improvement that compounds over years - Are interested in metabolic and cellular function as much as visible body composition

This stack is the most-studied, best-supported entry into mitochondrial bioenergetics research. The literature is dense; the practical effects are real but cumulative; the time horizon is months and years rather than weeks.

All three compounds are stocked through our laboratory partner network at research-grade purity. Each batch is HPLC and mass spectrometry verified. Certificates of Analysis available on every SKU.